FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
|Articles|December 9, 2014
CAR T-Cell Therapy for ALL
Author(s)Jae Park, MD
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.
Advertisement
Clinical Pearls
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.
- Adult patients with relapsed ALL have a poor prognosis overall survival is less than 10%.
- This CD-19-targeted CAR modified T-cell therapy elicited an 80% complete remission rate.
- The vast majority of these responses were MRD-negative.
<<<
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5